The buyout firm is exploring options for its 17% holding in Biotage, including a potential selldown of part or all of its shares in the market, according to the people. Shares of Biotage have gained 36% in Stockholm trading this year, giving the company a market value of about $1.4 billion.
KKR owns its stake through Gamma Biosciences, a platform it set up in 2020 to make investments in life sciences tools. Biotage has separately ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.